Advances in the hematopoietic stem cell (HSCs) field have been aided by methods to genetically engineer primary progenitor cells as well as animal models. Complete gene ablation in HSCs required the generation of knockout mice from which HSCs could be isolated, and gene ablation in primary human HSCs was not possible. Viral transduction could be used for knock-down approaches, but these suffered from variable efficacy. In general, genetic manipulation of human and mouse hematopoietic cells was hampered by low efficiencies and extensive time and cost commitments. Recently, CRISPR/Cas9 has dramatically expanded the ability to engineer the DNA of mammalian cells. However, the application of CRISPR/Cas9 to hematopoietic cells has been challenging, mainly due to their low transfection efficiencies, the toxicity of plasmidbased approaches and the slow turnaround time of virus-based protocols.
Introduction
The advent of CRISPR/Cas9 has radically simplified gene editing in mammalian cells. Early CRISPR/Cas9 protocols utilized plasmid or virusbased delivery of Cas9 protein and sgRNA 1, 2, 3 . These approaches proved revolutionary for the development of cellular and animal models and have been also successfully applied to primary hematopoietic stem and progenitor cells (HSPCs) 4, 5 . However, these methods have a number of drawbacks. First, gene disruption efficiency remains often below 50% 4, 5 . While this is sufficient for generating knockout (KO) clones in cell lines, the necessity for short-term culture makes HSPCs not amenable to such a strategy. Second, the requirement for cloning limits the amount of sgRNAs that can be tested in single experiments and generates large, difficult to transfect constructs. Third, these approaches force scientists to slow turnaround times. .
Incubate 1 x 10
8 viable cells per 1 mL ice-cold HBSS+ with biotin-conjugated c-kit antibody at 1:100 dilution for 45 min on ice.
8. Wash the cells with ice-cold HBSS+ by centrifuging at 400 x g for 7 min and discarding the supernatant. 9. Incubate the cells with anti-biotin magnetic beads following manufacturer instructions. 10 . Isolate c-kit positive cells using magnetic columns or magnetic-activated cell sorters following manufacturer instructions. Collect c-kit positive cells in 15 mL conical tubes. 11. Wash the cells twice with PBS by topping off the 15-mL conical tube and centrifuging at 400 x g for 7 min. Discard the supernatant.
Between the two washes calculate the total number of viable cells by trypan blue exclusion 9 . 12. Resuspend c-kit+ cells at a concentration of up to 10 6 viablecells per 100 µL of culture medium for murine HSPCs supplemented with 2% FBS, 50 ng/mL mouse stem cell factor (SCF), 50 ng/mL mouse thrombopoietin (TPO), 10 ng/mL mouse IL-3, and 10 ng/mL mouse IL-6. 13. Incubate the cells at 37 °C, 5% CO 2 for at least 1 h to a maximum of 24 h prior to the electroporation.
Human HSPCs isolation and culture
Note: These steps must be performed in a laminar flow hood. 1. Filter bone marrow/cord blood cells through a 40 µm cell strainer. 2. Dilute 1:2 the filtered bone marrow/cord blood cells with PBS supplemented with 1 mM EDTA (PBS/EDTA). 3. Dispense 15 mL of density gradient medium into a 50-mL conical tube. Gently pour 30 mL of the diluted bone marrow/cord blood on the density gradient medium surface. If the volume of cell suspension is greater than 30 mL prepare multiple tubes. Note: Make sure to keep the interface between the blood and the density gradient medium as sharp as possible. 4. Spin the tubes at 750 x g for 30 min with no deceleration. 5. Collect the mononuclear cell layer detectable at medium's interface and transfer to a clean 50 mL conical tube. Fill up the tube with PBS/EDTA and spin the cells at 280 g for 15 min. Discard the supernatant. 6. Wash the cells twice in PBS/EDTA spinning at 400 x g for 7 min and discarding the supernatant. 7. Incubate the mononuclear cells with anti-CD34 magnetic beads following manufacturer instructions. 8. Isolate CD34+ cells using magnetic columns or magnetic-activated cell sorters following manufacturer instructions. Collect CD34+ cells in 15 mL conical tubes. 9. Wash collected CD34+ cells twice by topping off the tube with PBS and spinning at 400 x g for 7 min and discarding the supernatant.
Between the two washes calculate the total number of viable cells by trypan blue exclusion 9 . 10. Resuspend the cells in culture medium supplemented with 100 ng/mL human SCF, 100 ng/mL human FLT3 ligand (FLT3L), 100 ng/mL human TPO at a concentration of ~2.5 x 10 5 viable cells/ml. Culture isolated CD34+ cells at 37 °C, 5% CO2 for 24 h to a maximum 48 h prior to electroporation. Note: Prior to electroporation check purity of enriched CD34+ population by flow cytometry.
Electroporation
Note: The following protocol is optimized for 10 µL electroporation tips. All steps should be performed in a laminar flow hood. 2. Wash cells twice with PBS, spinning at 300 x g for 7 min and carefully remove the supernatant. 3. In parallel, prepare Cas9-sgRNA RNP complexes by incubating in PCR tubes for 20 -30 min at RT 1.5 µg Cas9 with 1 µg of total sgRNA for each replicate, except the Cas9 only control. Note: Cas9 protein is provided at 10 µg/µl concentration. To ensure accurate pipetting, dilute 1:10 the total amount of Cas9 protein needed with nuclease-free water (e.g for 10 electroporations take 1 µl of Cas9 protein and dilute it with 9 µl of nuclease-free water and incubate 1 µl of diluted Cas9 per replicate. Depending on the concentration of the sgRNA, the total volume of Cas9 and sgRNA should be comprised between 1.7 and 2 µl per replicate. If using two sgRNAs incubate 500 ng of each sgRNA per replicate; if using 3 sgRNAs incubate 330 ng of each sgRNA per replicate, and so on. 4. Calculate the total volume of resuspension Buffer T needed by multiplying 10 µL by the number of total replicates needed (e.g. 30 µL for 3 replicates). Resuspend pelleted cells with the calculated volume of Buffer T. Ensure that the final concentration of the cell suspension is 2 x 10 7 cells/mL.
5. Aliquot 10 µL of resuspended cells/replicate into each PCR tube containing the pre-complexed sgRNA/Cas9 RNP (e.g. for a triplicate aliquot 30 μL of cell suspension into a PCR tube containing pre-complexed Cas9-sgRNA). 6. To set up the electroporation system turn on the instrument and add 3 mL of buffer E into an electroporation cuvette, and slide the cuvette into the cuvette holder. 7. Set the desired electroporation conditions on device: human HSPCs (1600 V, 10 ms, 3 pulses) or mouse HSPCs (1700 V, 20 ms, 1 pulse).
Note: If desired, before performing experiments on CD34+ HSPCs, sgRNA efficiency can be tested on acute myeloid leukemia (AML) cell lines (e.g. HL60) using the same strategy (use antibiotic-free medium for AML cell lines) with the following electroporation conditions: Buffer R, 1350 V, 35 ms, 1 pulse. 8. The electroporation is performed with a special electroporation pipette, which has a claw that latches onto the electroporation pipette tip. Hold the electroporation pipette, extend the claw, grab the disc inside the pipette tip, and then firmly press the pipette down to secure the tip. 9. Pipette the sample up and down 10 times to mix. Take out 10 µL, making sure there are no bubbles, and insert the pipette tip directly into the electrolytic buffer in the electroporation cuvette. Try not to touch the walls of the cuvette. Press "start" on the screen. After the "complete" 
Discussion
The RNP approach described in this detailed protocol enables efficient gene knockout in both mouse and human primary hematopoietic cells as well as in suspension cell lines. Although very high KO efficiencies are often obtained, several critical variables need to be considered. First, proper exon choice is key in guaranteeing that efficient indel incorporation corresponds to gene knockout. Two important factors related to exon choice are conservation across isoforms and exon position within transcripts. Isoform expression patterns are variable across cell types, so if gene KO across cell types is desired, exons that are invariant between cell types should be targeted. Isoform patterns can be verified using q-PCR or RNA-sequencing data. For exon position within transcripts, it is best to target early exons as frameshift mutations in the terminal or penultimate exon may escape nonsense-mediated decay 10 , producing proteins with novel or unknown functions rather than true nulls.
Determining the indel frequency is a critical step to estimate the KO efficiency and to correctly interpret the biological outcome of the experiment. Endonucleases assays (e.g. surveyor assay) have the advantage of being relatively fast and easy to perform. However, they tend to be inaccurate due to significant background signals and results are often difficult to reproduce. Moreover, they do not provide information on the quality of indels generated (e.g. length of insertions and deletions) in the experiment. Sanger sequencing provides a valuable alternative to endonuclease assays. Platforms such as TIDE 11 (https://tide.nki.nl/) help to decompose sanger traces and produce accurate estimates of allelic disruption efficiency, while also providing the frequencies of individual indels. The major drawback is an absolute dependence on highquality Sanger sequencing traces. High-throughput amplicon sequencing overcomes most of these issues. Amplicon libraries can be prepared starting with very low DNA inputs and the high coverage ensures reliable results. To reduce the cost of amplicon sequencing, we usually spike in amplicon libraries into larger sequencing runs (e.g. RNA-sequencing) using only 1 -1.5% of the total reads. Finally, to confirm successful knockout, we strongly recommend assessing protein levels by western blots or flow cytometry, when possible.
As previously described, the method presented here is fast and straightforward and represents a new tool to study gene knock out in mouse and human HSPCs. While our protocol provides instructions for gene knockout with a tip-based electroporation system, other systems have been demonstrated to be highly effective 12, 13 .
Two major limitations need to be acknowledged with respect to the RNP approach. First, as described by our group, the viability of HSPCs electroporated with in-vitro transcribed sgRNAs can be significantly compromised by electroporation, especially when conditions are not optimal 6 . If needed, commercially synthesized sgRNAs (i.e. eliminating in vitro transcription) may overcome this issue. These are becoming less expensive with time and can be purchased from several vendors. In this scenario, in vitro transcription could be used to generate a pool of sgRNA to screen for efficacy, and then the most efficient sgRNA(s) can be selected for synthesis. The second major limitation of the RNP approach is the inability to track successfully transfected cells, as in viral-based approaches. However, the high KO efficiency and rapid editing obtained with Cas9-sgRNA RNPs may outweigh these drawbacks in many experimental scenarios. We recommend using high-throughput amplicon sequencing to exactly determine the disruption efficiency in each experiment. If the knock-out of the gene of interest is expected to confer a proliferative phenotype (i.e. either reduced or increased proliferation compared to wild-type cells), determining the indel frequency at multiple time points allows one to assess whether KO cells undergo enrichment (i.e. indel frequency increases over time) or are outcompeted (i.e. indel frequency decreases over time).
Performing in vivo or in vitro experiments to understand the biological effects of loss of gene function requires the appropriate controls. As previously mentioned, in vitro transcribed sgRNAs may be toxic to cells, especially primary progenitor cells 6 . Additionally, DNA double-strand breaks caused by Cas9 protein can cause gene independent anti-proliferative response 14 . Therefore, we often use a number of control sgRNAs in CRISPR experiments and recommend a cell surface marker expressed on your cell type as well as a second target gene that is not expressed. efficiency KO. We have found 36 -48 hours to be the ideal period of culture prior to electroporation 6 . Following electroporation, the cells can be further cultured keeping in mind that the longer the culture the higher the risk of losing multilineage engraftment capacity. Therefore, we usually perform transplants 6 hours after electroporation and never later than 24 hours after electroporation.
CRISPR/Cas9 has dramatically improved the ability of scientists to successfully edit the genome of mammalian cells. Making gene disruption more feasible in primary hematopoietic progenitor cells is predicted to rapidly enhance the scientific knowledge in the field of HSPCs and hematologic diseases. Importantly, the protocol described here makes it also possible to simultaneously generate multiple knockouts with high efficiency, allowing for the modeling of complex genetic landscapes, often seen in leukemic diseases.
Although the protocols described herein are focused on gene disruption, they may be easily adapted for gene knock-in experiments. This can be accomplished through the co-delivery of single-stranded oligonucleotide templates for homology-directed repair 6, 13 (HDR) or through the transduction of cells post-electroporation with AAV6 vectors containing the homology template 12 . The ability to repair or introduce specific mutations in HSPCs will facilitate new therapeutic strategies for gene therapy and the expanded study of cancer driver mutations in AML and other hematologic diseases. While HDR in human HSPCs has been successfull 6, 12, 13 , mouse HSPCs have been difficult to edit using this strategy 6 . Optimization of HDR protocols in human and particularly in mouse HSPCs will enable more specific editing and the development of tools to track edited cells using endogenous tagging.
Finally, it is also envisioned that disruption of mutant gain-of-function alleles could represent a potential therapeutic approach for congenital and acquired hematopoietic disorders. In this scenario, a DNA-free approach is advised in order to avoid possible integrations that could promote transformation. Moreover, the "hit and run" approach reduces the possibility of undesired off-target effects. More effort is needed in order to develop specific delivery systems that would open new avenues for the treatment of malignant and non-malignant hematologic diseases.
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